Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis
- PMID: 20156360
- PMCID: PMC2875535
- DOI: 10.1186/cc8877
Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis
Abstract
Introduction: The main objective was to determine risk factors for presence of multidrug resistant bacteria (MDR) in postoperative peritonitis (PP) and optimal empirical antibiotic therapy (EA) among options proposed by Infectious Disease Society of America and the Surgical Infection Society guidelines.
Methods: One hundred patients hospitalised in the intensive care unit (ICU) for PP were reviewed. Clinical and microbiologic data, EA and its adequacy were analysed. The in vitro activities of 9 antibiotics in relation to the cultured bacteria were assessed to propose the most adequate EA among 17 regimens in the largest number of cases.
Results: A total of 269 bacteria was cultured in 100 patients including 41 episodes with MDR. According to logistic regression analysis, the use of broad-spectrum antibiotic between initial intervention and reoperation was the only significant risk factor for emergence of MDR bacteria (odds ratio (OR) = 5.1; 95% confidence interval (CI) = 1.7 - 15; P = 0.0031). Antibiotics providing the best activity rate were imipenem/cilastatin (68%) and piperacillin/tazobactam (53%). The best adequacy for EA was obtained by combinations of imipenem/cilastatin or piperacillin/tazobactam, amikacin and a glycopeptide, with values reaching 99% and 94%, respectively. Imipenem/cilastin was the only single-drug regimen providing an adequacy superior to 80% in the absence of broad spectrum antibiotic between initial surgery and reoperation.
Conclusions: Interval antibiotic therapy is associated with the presence of MDR bacteria. Not all regimens proposed by Infectious Disease Society of America and the Surgical Infection Society guidelines for PP can provide an acceptable rate of adequacy. Monotherapy with imipenem/cilastin is suitable for EA only in absence of this risk factor for MDR. For other patients, only antibiotic combinations may achieve high adequacy rates.
Figures


Similar articles
-
Microbiological profile of patients treated for postoperative peritonitis: temporal trends 1999-2019.World J Emerg Surg. 2023 Dec 19;18(1):58. doi: 10.1186/s13017-023-00528-1. World J Emerg Surg. 2023. PMID: 38115142 Free PMC article.
-
Epidemiology and risk factors of multidrug-resistant bacteria in respiratory samples after lung transplantation.Transpl Infect Dis. 2016 Feb;18(1):22-30. doi: 10.1111/tid.12471. Epub 2016 Jan 30. Transpl Infect Dis. 2016. PMID: 26455730
-
[Bacteriological profile and antibiotic treatment of postoperative peritonitis].Arch Inst Pasteur Tunis. 2014;91(1-4):57-66. Arch Inst Pasteur Tunis. 2014. PMID: 26485771 French.
-
Current guidelines for the treatment of severe pneumonia and sepsis.Chemotherapy. 2005 Aug;51(5):227-33. doi: 10.1159/000087452. Chemotherapy. 2005. PMID: 16103664 Review.
-
Spontaneous bacterial peritonitis caused by Gram-negative bacteria: an update of epidemiology and antimicrobial treatments.Expert Rev Gastroenterol Hepatol. 2019 Jul;13(7):683-692. doi: 10.1080/17474124.2019.1621167. Epub 2019 May 29. Expert Rev Gastroenterol Hepatol. 2019. PMID: 31107612 Review.
Cited by
-
Are enterococci playing a role in postoperative peritonitis in critically ill patients?Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1479-85. doi: 10.1007/s10096-011-1467-8. Epub 2011 Nov 12. Eur J Clin Microbiol Infect Dis. 2012. PMID: 22076551
-
What every intensivist should know about the management of peritonitis in the intensive care unit.Rev Bras Ter Intensiva. 2018 Mar;30(1):9-14. doi: 10.5935/0103-507x.20180007. Rev Bras Ter Intensiva. 2018. PMID: 29742214 Free PMC article. No abstract available.
-
The challenge of post-operative peritonitis after gastrointestinal surgery.Updates Surg. 2015 Dec;67(4):373-81. doi: 10.1007/s13304-015-0324-1. Epub 2015 Aug 12. Updates Surg. 2015. PMID: 26264821 Review.
-
The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections.World J Emerg Surg. 2017 Jul 10;12:29. doi: 10.1186/s13017-017-0141-6. eCollection 2017. World J Emerg Surg. 2017. PMID: 28702076 Free PMC article. Review.
-
Prevalence of and risk factors for biliary carriage of bacteria showing worrisome and unexpected resistance traits.J Clin Microbiol. 2013 Feb;51(2):518-21. doi: 10.1128/JCM.02469-12. Epub 2012 Nov 28. J Clin Microbiol. 2013. PMID: 23196362 Free PMC article.
References
-
- Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, Buchman T, Dellinger EP, Jernigan J, Gorbach S, Chow AW, Bartlett J. Infectious Diseases Society of America. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis. 2003;37:997–1005. doi: 10.1086/378702. - DOI - PubMed
-
- Mazuski JE, Sawyer RG, Nathens AB, DiPiro JT, Schein M, Kudsk KA, Yowler C. Therapeutic Agents Committee of the Surgical Infections Society. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect (Larchmt) 2002;3:161–173. doi: 10.1089/109629602761624171. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous